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Background/Aims: The prognostic factors in primary duodenal adenocarcinoma remain controversial. This study
evaluated the prognostic factors associated with survival in patients with primary duodenal adenocarcinoma.
Methods: From March 1996 to June 2008, the medical records of 30 patients with a final diagnosis of primary
duodenal epithelial malignancy seen at two referral centers were reviewed retrospectively. The prognostic factors
for survival were evaluated 6 months and 1, 2, and 5 years after the diagnosis. 
Results: The median survival was 5.7 months. The survival rate was 46.7% (14/30), 16.7% (5/30), 10% (3/30),
and 6.7% (2/30) at 6 months and 1, 2, and 5 years, respectively. Multivariate analysis showed that cancer-direct-
ed treatment, including curative surgery or chemotherapy, was a common independent risk factor at all follow-up
times. Total bilirubin, cytology, and TNM stage were independent risk factors for survival at 1, 2, and 5 years.
The white blood cell count was an independent risk factor at 1 year only. The actuarial probability of survival in
patients undergoing cancer-directed treatment was significantly higher than in those without treatment at 6
months (71.4 vs. 25.0%, p < 0.01), 1 year (28.6 vs. 6.3%, p < 0.01), 2 years (21.4 vs. 0%, p < 0.01), and 5 years
(14.3 vs. 0%, p < 0.01).
Conclusions: The prognostic factors in patients with primary duodenal adenocarcinoma were total bilirubin,
TNM stage, cytology, and cancer-directed treatments until the 5-year follow-up. Especially, cancer-directed treat-
ments improved patient survival. (Korean J Intern Med 2011;26:34-40)
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INTRODUCTION
Primary duodenal adenocarcinoma is a rare malignant
neoplasm; it accounts for 0.3% of all gastrointestinal tract
carcinomas and 33-45% of all small-intestine carcinomas
[1-5]. Its poor prognosis is likely associated in part with
the frequently delayed diagnosis, which results from the
difficulty making a diagnosis, as patients often present
with non-specific symptoms or signs not suggesting the
need for upper gastrointestinal endoscopy [6-8]. Due to
the rarity of this malignancy, the prognostic factors associ-
ated with survival remain controversial [8]. Curative
resection is accepted as the only potential cure for this dis-
ease. In addition to surgery, other suggested prognostic
factors include the disease stage, cytology, smoking histo-
ry, aspartate transaminase (AST), and weight loss,
although the significance of each factor is debated [4,7]. In
practice, some patients do not undergo surgery due to the
high operative risk because of advanced age or comorbidi-
ty. In addition, patients with a delayed diagnosis often
choose non-surgical care. This study determined the prog-
nostic factors associated with survival in patients with pri-
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mary duodenal adenocarcinoma.
METHODS
The database on patients with primary malignant
tumors of the duodenum, excluding carcinoma of the
ampulla of Vater, was reviewed at two referral centers, St.
Vincent’s Hospital and Seoul St. Mary’s Hospital, between
March 1996 and June 2008. Both are university-affiliated
hospitals. The patients with histologically confirmed ade-
nocarcinoma were enrolled.
We retrospectively reviewed the patients' records and
charts and the digitalized picture archiving communica-
tion system (PACS) (Fig. 1), which revealed the demo-
graphics, including age, gender, body mass index (BMI),
smoking history, presenting symptoms, laboratory find-
ings, TNM stage, the tumor characteristics, including size,
location, and cytology, and the treatment modality at the
first visit to our clinic. The duration of survival was also
reviewed. The primary outcomes were the factors predict-
ing survival at 1 and 5 years in the patients with primary
duodenal adenocarcinoma. The institutional review board
approved this study. The inclusion criteria were histologi-
cally proven duodenal adenocarcinoma and an age greater
than 18 years, no history of underlying malignancy, and
complete medical records available during follow-up.
The data were expressed as the median (range) or mean
± SD. Continuous variables were analyzed using indepen-
dent-sample t tests. Categorical variables were analyzed
using the χ
2 test or Fisher’s exact test. To evaluate the
actuarial probability of survival, the Kaplan-Meier method
with the log-rank test was used. To determine the inde-
pendent risk factors for survival, a Cox regression propor-
tional hazard analysis was used. The odds ratio (OR) and
95% confidence interval (CI) were calculated. Analyses
were performed with SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA). A p value less than 0.05 was consid-
ered significant for all tests.
RESULTS
Patients
During the study period, there were 44 patients with
primary epithelial malignancies of the duodenum. Of
these, 14 patients were excluded due to transfer to other
clinics (n = 3), non-adenocarcinoma-type histology con-
firmed as squamous cell cancer (n = 1), double primary
cancer (n = 2), and incomplete data (n = 8). Thirty
patients were analyzed over a median survival period of
5.7 (range, 0.3 to 121) months. The mean age of the
Figure 1. Endoscopic view of the duodenum showing focal segmental luminal narrowing with a reddish area with mucosal irregularity
(white arrow) just below the ampulla of Vater (black arrow) (A). Abdominal CT demonstrating marked common bile duct dilatation
with suspicious focal segmental duodenal wall thickening (arrow) at the periampullary area (B).
A B36 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
patients was 68.6 ± 13.3 (range, 30 to 90) years. The
male-to-female ratio was 2.75:1. The median duration of
symptoms before the initial hospital visit was 2 (range, 0.1
to 16) months. There were 3, 5, 9, and 14 patients at TNM
stages I to IV, respectively. Abdominal pain was the pre-
dominant symptom in 22 patients (73%), followed by nau-
sea in six (20%), weight loss in six (20%), jaundice in five
(17%), vomiting in four (13%), fever in three (10%), and
signs of gastrointestinal bleeding in two patients (7%).
Surgery was performed in 14 patients; five patients
(35.7%) underwent curative surgery including the
Whipple's operation in four patients and pylorus-preserv-
ing pancreaticoduodenectomy in one patient, and nine
patients (64.3%) underwent a palliative gastrojejunosto-
my. Cancer-directed treatments including curative
surgery or chemotherapy were performed in 14 patients
(46.7%): three had surgery only, nine had chemotherapy
only, and two patients had both surgery and chemothera-
py. For palliative treatment, biliary drainage was per-
formed in 12 patients (40%). Among these patients, one
patient underwent percutaneous transhepatic biliary
drainage, eleven had percutaneous transhepatic cholan-
gitic drainage, and four required a subsequent stent inser-
tion. The mortality rate was 53.3% (16/30) at 6 months,
83.3% (25/30) at 1 year, 90.0% (27/30) at 2 years, and
93.3% (28/30) at 5 years. The baseline factors and patient
survival at five years are shown in Table 1.
Survival at 6 months and 1, 2, and 5 years
The survival rate was 46.7% (14/30), 16.7% (5/30), 10%
Table 1. Demographics at the 5-year follow-up
Died (n = 28) Survived (n = 2) p valuea
Age, yr  68.3 ± 13.3 73.0 ± 11.3 0.89
Sex (male/female) 22/6 0/2 0.06
BMI  22.4 ± 2.9 26.0 ± 0.9 0.56
Smoking 0.61
Yes 4 0
No 23 2
Symptom interval, mon  2.7 ± 3.5 4.1 ± 5.6 0.19
WBC, × 10
6/µL 8,231 ± 3,275 7,500 ± 1,142 0.56
ALT, IU/L 84 ± 128 12 ± 2 0.35
Alk-p, IU/L 604 ± 704 258 ± 12 0.37
TB, mg/dL 3.5 ± 5.1 0.5 ± 0.2 0.34
Albumin, g/dL 3.6 ± 0.6 4.5 ± 0.2 0.07
Amylase, IU/L 101 ± 118 62 ± 36 0.86
Stage 0.49
IV 13 0
Non-IV 15 2
Cytology 0.78
PD 9 1
Non-PD 19 1
Surgery 0.02
Yes 3 2
No 25 0
Chemo TX 1.00
Yes 18 1
No 10 1
CDT 0.20
Yes 12 2
No 16 0
BMI, body mass index; WBC, white blood cell count; ALT, alanine transaminase; Alk-p, alkaline phosphatase; TB, total bilirubin; PD, poorly differ-
entiated adenocarcinoma; Chemo TX, chemotherapy; CDT, cancer-directed treatments.
aExpressed as the mean ± SD and calculated using the independent-samples t test, χ
2 test or Fisher’s exact test. 
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(3/30), 6.7% (2/30) at the 6-month and 1-, 2-, and 5-year
follow-up, respectively. In the univariate survival analysis,
the white blood cell (WBC) count and cancer-directed
treatments were significantly correlated with survival at all
four times (Table 2). In the multivariate Cox proportional
hazard model logistic regression analysis, cancer-directed
treatment was the only independent factors associated
with survival at 6 months. Common independent factors
predicting continued survival at 1, 2, and 5 years were the
total bilirubin, disease stage, cytology, and cancer-directed
treatment. In addition, the WBC count was an indepen-
dent factor associated with survival at 1 year (Table 3).
The actuarial probability curves for continued survival
in the patients who received cancer-directed treatment
were significantly higher than in the patients without can-
cer-directed treatment at 6 months (71.4 vs. 25.0%, p <
0.01, log-rank test), 1 year (28.6 vs. 6.3%, p < 0.01, log-
rank test), 2 years (21.4 vs. 0%, p < 0.01, log-rank test),
and 5 years (14.3 vs. 0%, p< 0.01, log-rank test) (Fig. 2).
DISCUSSION
The results of this study, which included an evaluation
of demographic information, laboratory studies,
histopathological characteristics, and treatment modali-
ties (including chemotherapy and curative surgery)
showed that the prognostic factors for survival at 1 and 5
years were related to cancer-directed treatment, including
chemotherapy and curative surgery, total bilirubin, cytol-
ogy, and TNM stage.
Primary duodenal adenocarcinoma, excluding the
ampulla of Vater, remains a rare disease characterized by
vague, non-specific symptoms and delayed diagnosis
[7,9,10]. Its characteristics lead to a low resectability
potential for the primary lesion and a poor patient prog-
nosis. The literature suggests that the most common
symptoms in patients with small bowel tumors or a duo-
denal malignancy are abdominal pain, consistent with our
findings [7,11]. Although improved diagnostic techniques
might increase the frequency of recognized disease, the
unique anatomy of the duodenum [12] and overlooked
overview of upper endoscopy limit the possibility of an
early diagnosis and curative resection in many patients
with these malignancies [8]. Identifying the factors pre-
dicting survival is important for managing patients with
malignancies. However, the prognostic factors associated
with primary duodenal adenocarcinoma remain contro-
versial. We analyzed patients with primary duodenal car-
cinoma to evaluate the clinical course and risk factors
associated with survival in these patients at 1 and 5 years.
Cancer-directed treatment was defined as curative
surgery or chemotherapy that could affect debulking of
the cancer itself. Cancer-directed treatment excluded pal-
liative surgery, all nine cases of which involved a palliative
gastrojejunostomy as bypass surgery only. The cancer-
directed treatment included all cases of chemotherapy
because the chemotherapy affects the cancer itself irre-
spective of palliative or curative intent.
Among the 14 excluded patients, eight patients under-
going hospice care only were excluded due to incomplete
medical data. Although our study excluded patients that
Table 2. Univariate survival analysis at the 6-month and 1-, 2-, and 5-year follow-up (p valuea)
6-mon 1-yr 2-yr 5-yr
Age, yr (< or ≥ 65) 0.17 0.17 0.25 0.32
Sex (male or female)  0.79 0.13 0.09 0.09
WBC (< or ≥ 10,000 × 10
6/µL) 0.04 0.03 0.03 0.02
ALT (≤ 45 or > 45 IU/L) 0.95 0.35 0.35 0.34
Alk-p (≤ or > 400 IU/L) 0.06 0.04 0.04 0.04
TB (≤ or > 1.2 mg/dL) 0.09 0.06 0.06 0.06
Albumin (≤ or > 3.2 g/dL) 0.02 0.10 0.06 0.06
Stage (IV or non-IV) 0.67 0.19 0.19 0.01
Cytology (PD or non PD) 0.91 0.37 0.51 0.62
Surgery (yes or no) 0.28 0.03 0.01 0.01
Chemo TX (yes or no) 0.03 0.15 0.18 0.15
CDT (yes or no) < 0.001 < 0.01 < 0.01 < 0.01
WBC, white blood cell count; ALT, alanine transaminase; Alk-P, alkaline phosphatase; TB, total bilirubin; PD, poorly differentiated adenocarcinoma;
Chemo TX, chemotherapy; CDT, cancer-directed treatments.
aCalculated using the Kaplan-Meier method with the log-rank test.38 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
had extremely poor health and were not eligible for treat-
ment of their malignancy, such as those receiving hospice
care, we found low survival rates of 16.7% at 1 year and
6.7% at 5 years, compared with reported survival rates of
28.9% at 1 year and 7.9% at 5 years [7]. The high rate of
curative resection in the prior study (47.8%), compared
with our study (5 in 30 patients, 16.7%), may explain the
better survival rate. In addition, our patients reported a
long duration of symptoms, a mean of 2.8 months, before
the initial diagnosis, compared with 1.6 months reported
in the literature [7]. Furthermore, there was a relatively
high proportion of patients with TNM stage III or IV dis-
ease (73.3%, 22 of 30) and non-specific symptoms, with
abdominal pain in 70% of cases; these factors might have
led to the low rate of curative resection. There is general
agreement that surgery remains the only potential cure for
patients with duodenal carcinoma [2,3,12-19], and prior
studies support an aggressive surgical approach once the
diagnosis is confirmed [12,13]. The survival rate of 40% in
patients who underwent curative resection (two of five
patients) at the 5-year follow-up in our study was compa-
rable to the 42% reported previously [13].
This study showed that the common independent posi-
tive factor predicting survival at all follow-up periods (i.e.,
6 months and 1, 2, and 5 years) was cancer-directed treat-
ment. In addition, independent factors for survival from 1
through 5 years included total bilirubin < 1.2 mg/dL,
cytology showing no poorly differentiated adenocarcino-
ma, and TNM stage < IV. The WBC count was a signifi-
cant factor for survival only at 1 year, but tended to corre-
Figure 2. Actuarial probability curve of continued survival in patients with primary duodenal carcinomas after 6 months (A), 1 year
(B), 2 years (C), and 5 years (D). Patients with cancer-directed treatment versus those without cancer-directed treatment compared
using the log-rank test at 6 months (71.4 vs. 25.0%, p < 0.01), 1 year (28.6 vs. 6.3%, p < 0.01), 2 years (21.4 vs. 0%, p < 0.01), and 5
years (14.3 vs. 0%, p < 0.01).
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late with survival at 2 and 5 years (p= 0.07). Although risk
factors reported to be associated with the prognosis of
duodenal adenocarcinoma include complete tumor resec-
tion [2,12,20], tumor stage [12,16,21-23], weight loss [7],
cytology [7], smoking history [7], and AST [7], most of the
previous studies focused on the risk factors with regard to
the resectability of the primary lesion. The identification of
the WBC count as a risk factor was new to our study. One
paper suggested that medical conditions such as adeno-
carcinoma are a bowel risk factor. In our study, the WBC
count was no longer a significant factor at the relatively
long-term follow-up periods of 2 and 5 years, which
implies that it has a minor effect on survival.
In clinical practice, some patients are reluctant to
undergo surgery due to advanced age or high operative
risk; these patients frequently choose non-surgical care.
The general medical status of patients at the initial diag-
nosis and the treatment modalities used are important
factors to consider when evaluating the patient prognosis.
For example, chemotherapy is an important method of
treatment for patients with malignancies. Therefore, we
included demographics, clinical findings, laboratory data,
pathology results, and treatment modality in our study.
As with any retrospective study, this study has certain
limitations. A lack of defined criteria for determining the
operative or chemotherapeutic modalities and for select-
ing various therapeutic modalities was a major limitation.
The small number of enrolled patients and the loss of
eight subjects due to incomplete data were other limita-
tions.
Despite the limitations, this retrospective study of the
short- and long-term follow-up of patients with primary
duodenal carcinoma provides insight into the factors pre-
dicting survival at 6 months and 1, 2, and 5 years. Although
only a minority of the patients had cancer-directed treat-
ments in clinical practice, curative resection and
chemotherapy improved the survival rates and should be
considered for eligible patients to prolong survival.
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